文献速递慢性肾脏病肾移植

尿DKK3作为肾功能下降生物标志物的系统评价与荟萃分析

Urinary Dickkopf-3 as a biomarker for kidney-function decline: a systematic review and meta-analysis.
PubMed 文献 · Nephrol Dial Transplant · 2026-08-07

该系统评价与荟萃分析纳入24项全文研究及6项摘要等,评估尿DKK3与肾功能下降、纤维化及移植结局的关联。汇总8项原生肾脏估计显示,较高uDKK3与肾功能下降或进展相关(合并相对效应1.82,95%CI 1.44-2.30)。3项活检队列中纤维化相关性方向为正但不精确。结论支持uDKK3作为补充性肾小管应激标志物用于风险富集,而非替代eGFR和白蛋白尿。

要点

  • 较高尿DKK3与肾功能下降或进展相关,合并相对效应1.82(95%CI 1.44-2.30)。
  • 活检队列中uDKK3与纤维化相关性方向为正但不精确(r=0.62,95%CI -0.04至0.91)。
  • uDKK3应作为eGFR和白蛋白尿之外的补充性肾小管应激标志物。

核心结论

  • 较高uDKK3与肾功能下降一致相关,并在活检队列中显示纤维化富集信号,支持其作为补充性肾小管应激标志物用于风险富集,而非替代eGFR和白蛋白尿。
  • 证明增量临床价值需 assay-aware 解读、跨平台协调、人群特异性截断值验证及前瞻性效用测试。

研究设计与样本

  • 系统评价与荟萃分析,检索PubMed、Embase、CENTRAL/Cochrane、ClinicalTrials.gov及会议来源至2026年5月28日。
  • 纳入24项全文研究、6项独特摘要及相关注册/母试验记录,使用QUIPS评估偏倚风险。
  • 主要进展合成采用Paule-Mandel随机效应及HKSJ区间,每队列纳入一个阈值/分类HR或OR;纤维化相关性采用Fisher-z合并。

主要发现

  • 8项原生肾脏估计中,较高uDKK3与肾功能下降或进展相关,合并相对效应(HR/OR复合)1.82(95%CI 1.44-2.30;I2=32%;95%预测区间1.15-2.89)。
  • 仅HR敏感性估计为1.70(95%CI 1.20-2.41)。
  • 3项活检队列中,合并纤维化相关性方向为正但不精确(r=0.62,95%CI -0.04至0.91;常规CI 0.36-0.80;I2=86%)。
  • assay分层分析在ReFiNE/DiaRen或尿液验证 assay 及其他/RUO/不明确平台中方向均为正,但区间重叠且不精确。
  • 病理判别研究支持纤维化富集信号而非纤维化特异性信号;预测和移植数据有前景但较不成熟。

关键数值与推荐

  • 原生肾脏合并相对效应(HR/OR复合)1.82(95%CI 1.44-2.30),I2=32%,95%预测区间1.15-2.89。
  • HR-only敏感性估计1.70(95%CI 1.20-2.41)。
  • 活检队列纤维化相关性r=0.62(95%CI -0.04至0.91),I2=86%。

临床怎么用

  • 可将uDKK3视为与eGFR和白蛋白尿并列的补充性肾小管应激标志物,用于风险富集而非替代现有指标。
  • 临床解读需考虑检测平台差异,并等待跨平台协调及人群特异性截断值验证。

局限性

  • assay平台异质性大,分层分析区间重叠且不精确。
  • 活检队列纤维化相关性经HKSJ校正后不精确,异质性高(I2=86%)。
  • 预测和移植数据较不成熟,增量临床价值尚未在前瞻性研究中验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Urinary Dickkopf-3 (uDKK3) is a tubular-stress glycoprotein linked experimentally to tubular injury, context-dependent Wnt signaling and tubulointerstitial remodeling. Human studies now span CKD, kidney histology, cardiorenal disease and transplantation, but the clinical estimands and assay platforms differ. METHODS: We searched PubMed, Embase, CENTRAL/Cochrane, ClinicalTrials.gov and conference sources to 28 May 2026 for human urinary DKK3 studies reporting kidney-function decline/progression, kidney failure, fibrosis/histology or transplant/donor outcomes. Risk of bias was assessed with QUIPS. The primary progression synthesis pooled one threshold/categorical HR or OR per cohort using Paule-Mandel random effects with HKSJ intervals; fibrosis correlations were Fisher-z pooled. We also performed an exploratory assay-aware sensitivity analysis using platform classifications extracted from the source articles. RESULTS: We included 24 full-text studies, 6 unique abstracts and relevant registry/parent-trial records. Across 8 native-kidney estimates, higher uDKK3 was associated with kidney-function decline or progression (pooled relative effect [HR/OR composite] 1.82, 95% CI 1.44-2.30; I2=32%; 95% prediction interval 1.15-2.89). The HR-only sensitivity estimate was 1.70 (95% CI 1.20-2.41). Assay-stratified analyses were directionally positive in ReFiNE/DiaRen or urine-validated assays and in other/RUO/unclear platforms, with overlapping and imprecise intervals. In 3 biopsy cohorts, the pooled fibrosis correlation was directionally positive but imprecise after HKSJ correction (r=0.62, 95% CI -0.04 to 0.91; conventional CI 0.36-0.80; I2=86%). Pathology-discrimination studies supported a fibrosis-enriched, rather than fibrosis-specific, signal. Prediction and transplant data were promising but less mature. CONCLUSIONS: Higher uDKK3 was consistently associated with kidney-function decline and showed a fibrosis-enriched signal in biopsy cohorts, supporting its use as a complementary tubular-stress biomarker for risk enrichment alongside, not instead of, eGFR and albuminuria. Demonstrating incremental clinical value will require assay-aware interpretation, cross-platform harmonization, population-specific cut-off validation and prospective tests of utility.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Shang Y, Wang B, Huang Y, et al. Urinary Dickkopf-3 as a biomarker for kidney-function decline: a systematic review and meta-analysis. Nephrol Dial Transplant. 2026. PMID: 42566260. doi:10.1093/ndt/gfag178

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。